Furthermore, Rgs2+CD8+ T cells and Rgs2−CD8+ T cells were separated from mice that underwent RegoNeo therapy, using flow cytometry sorting and assessed for tumor‐killing and cytokine secretion ability. This evidence concerns the gene RGS2 and neoplasm.